Venous ulcers are the terminal phase of chronic venous insufficiency, the result of induced skin disorders and maintained by persistent venous hypertension. Affecting a large part of the adult population, they drain economic resources and greatly impact patient quality of life.The objective of this descriptive, retrospective case series was to determine the efficacy of recombinant human epidermal growth factor (rhEGF) plus compression therapy vs standard of care in 48 patients with active ulcers resulting from chronic venous insufficiency.

In this descriptive, retrospective case series, 24 patients (mean age, 62.4 years) received rhEGF by intralesional and perilesional infiltration with compression therapy, and 24 patients (mean age, 69.4 years) received treatment with topical hydrocolloid gels and compression therapy. In 62.5% of patients, the ulcers were located in the internal malleoli. Ulcer progression time, ulcer size, Wollina score index, number of conventional cures, rhEGF vials used, and time to epithelialization were documented.

According to sex, it is observed in the two groups that females are predominant. they were predominantly observed at the level of the internal and external malleoli with 75% and 83% in the Epiprot® treatment group and in the conventional therapy group, respectively.with more than 60%, of the active ulcer was reached in 100% of intervened patients. In the 24 patients receiving rhEGF, 71% achieved wound closure in 8 weeks or less, and the remaining percentage achieved closure within 9 and 12 weeks. In the conventional therapy group, patients achieved closure in an average of 29.5 weeks, with a minimum of 13 weeks and a maximum of 46 weeks.

The use of therapy with Human Recombinant Epidermal Growth Factor and compressive therapy allows to obtain total epithelialization of chronic venous ulcers in a time equal to or less than 12 weeks of treatment, compared with the use of conventional therapy with the use of hydrocolloids and compressive therapy.

1. Valencia IC, Falabella A, Kirsner RS, Eagl- stein WH. Chronic venous insufficiency and venous leg ulceration. J Am Acad Dermatol. 2001;44(3):401-421. doi:10.1067/mjd.2001.111633 2. Aguiar ET, Pinto LJ, Figueiredo MA, Savino NS. Úlcera de insuficiência venosa crônica. Diretrizes sobre diagnóstico, prevenção e tratamento da Socieda de Brasileira de Angio- logia e Cirurgia Vascular (SBACV). J Vasc Br. 2005;4(Supl.2):S195-S200. 3. Muñoz García R. Tratamiento de las ulceras venosas. Universidad Internacional de Anda- lucía, Edición electrónica 2017. https://dspace. unia.es/bitstream/handle/10334/3734/0773_ Mu%C3%B1oz.pdf 4. Roura JM. Úlceras de la Extremidad Inferior. 2nd ed. Editorial Glosa SL; 2011: 35. 5. Casals Solé FJ. Úlceras vasculares: Venosas. Úlceras. Accessed January 4, 2021. https://www. ulceras.net/monografico/103/91/ulceras-vascu- lares-venosas.html. 6. Asociación española de cirugía vascular y heridas. Guía de práctica clínica. Consenso sobre ulceras vasculares y pie diabético. Tercera edición. AEEVH; 2017.